Walshe R - Search Results

1

Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.

Müller D, Fischer K, Kaiser P, Eichhorst B, Walshe R, Reiser M, Kellermann L, Borsi L, Civello D, Mensch A, Bahlo J, Hallek M, Stock S, Fingerle-Rowson G. Müller D, et al. Among authors: walshe r. Leuk Lymphoma. 2016 May;57(5):1130-9. doi: 10.3109/10428194.2015.1070151. Epub 2015 Nov 20. Leuk Lymphoma. 2016. PMID: 26584689

2

A cost calculation model for specialist palliative care for patients with non-small cell lung cancer in a tertiary centre.

Ostgathe C, Walshe R, Wolf J, Hallek M, Voltz R. Ostgathe C, et al. Among authors: walshe r. Support Care Cancer. 2008 May;16(5):501-6. doi: 10.1007/s00520-007-0337-5. Epub 2007 Oct 2. Support Care Cancer. 2008. PMID: 17909863

3

Cost of illness of malignant lymphoma in Germany.

Reis A, Ihle P, Paulus U, Ferber LV, Diehl V, Walshe R. Reis A, et al. Among authors: walshe r. Eur J Cancer Care (Engl). 2006 Sep;15(4):379-85. doi: 10.1111/j.1365-2354.2006.00676.x. Eur J Cancer Care (Engl). 2006. PMID: 16968321

4

[Therapy of Hodgkin's disease. Optimization over 4 study generations].

Diehl V, Wolf J, Walshe R, Tesch H, Löffler M. Diehl V, et al. Among authors: walshe r. Internist (Berl). 1998 Sep;39(9):917-26. doi: 10.1007/s001080050261. Internist (Berl). 1998. PMID: 9788113 Review. German. No abstract available.

5

Can factors influencing in-patient treatment in Hodgkin's disease be identified?--Retrospective analysis of HD6 patients of the GHSG.

Pfistner B, Paulus U, Glossmann JP, Walshe R, Tesch H, Diehl V; German Hodgkin Study Group. Pfistner B, et al. Among authors: walshe r. Stud Health Technol Inform. 2000;77:399-403. Stud Health Technol Inform. 2000. PMID: 11187583 Clinical Trial.

6

A new approach to safeguard high standards and cost containment of stem cell transplantation in Germany.

Diehl V, Walshe R, Schmitz N. Diehl V, et al. Among authors: walshe r. Ann Oncol. 1999 May;10(5):609. doi: 10.1023/a:1026450730432. Ann Oncol. 1999. PMID: 10416015 Free article. No abstract available.

7

[Economic evaluation within the scope of clinical studies].

Walshe R, Diehl V. Walshe R, et al. Internist (Berl). 1998 Sep;39(9):943-54. doi: 10.1007/s001080050264. Internist (Berl). 1998. PMID: 9788116 Review. German. No abstract available.

8

Can corporatization contribute to quality assurance and cost control in the German hospital sector? A pilot project for stem cell transplantation.

Walshe R, Schmitz N, Diehl V. Walshe R, et al. Health Policy. 1999 Sep;48(3):207-18. doi: 10.1016/s0168-8510(99)00051-2. Health Policy. 1999. PMID: 11067039 No abstract available.

9

[True medicine? Economic analysis and perspectives for medical service].

Walshe R, Waldschmidt D, Diehl V. Walshe R, et al. Unfallchirurg. 2000 Apr;103(4):334-40. doi: 10.1007/s001130050546. Unfallchirurg. 2000. PMID: 10851963 German. No abstract available.

10

[Current developments in hematology and internal medicine oncology].

Walshe R, Engert A, Diehl V. Walshe R, et al. Internist (Berl). 1998 Apr;39(4):346-54. doi: 10.1007/s001080050180. Internist (Berl). 1998. PMID: 9599744 Review. German. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page